In this episode of DeviceTalks, we speak with Richard Thompson, CEO of ReShape Medical, about the company’s bariatric surgery alternative for people suffering from obesity.
In July, San Clemente, Calif.-based ReShape won pre-market approval from the FDA for its dual balloon system, indicated to facilitate weight loss in obese adult patients. The system is designed to be inserted endoscopically into the stomach, where it remains for 6 months to help patients feel full. The balloon is meant to be temporary and patients with the device undergo supervised diet and exercise plans to maintain weight loss following its removal, according to ReShape.
Last week, the company added another $38 million to its war chest in a Series D round led by HealthCor Partners Management. Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors also participated.
In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson discusses ReShape’s procedure, the difficulty of combating obesity and why Thompson feels this treatment will work where so many others have failed. Thompson will be a featured speaker at our DeviceTalks live event Dec. 9 in Orange County, Calif.